|1.||Nakashima, Taku: 2 articles (01/2014 - 07/2011)|
|2.||Fioravanti, Mario: 2 articles (01/2014 - 01/2008)|
|3.||Zajdel, Paweł: 1 article (04/2015)|
|4.||Sapa, Jacek: 1 article (04/2015)|
|5.||Bednarski, Marek: 1 article (04/2015)|
|6.||Nowak, Gabriel: 1 article (04/2015)|
|7.||Xu, Jun: 1 article (01/2014)|
|8.||Garg, Amit: 1 article (01/2014)|
|9.||Rastenyte, Daiva: 1 article (04/2013)|
|10.||Petrikonis, Kestutis: 1 article (04/2013)|
02/01/1995 - "In a double-blind, placebo-controlled study on the therapeutic efficacy and central effects of nicergoline, an ergot alkaloid with metabolic, antithrombotic and vasoactive action, 112 patients with mild to moderate dementia, diagnosed according to DSM III-R criteria (MMS 13-25), living in pensioners' homes, were included. "
04/01/1989 - "In view of some controversies still existing about the real efficacy of ergot derivatives in the management of dementia, a double-blind, randomized, parallel group trial extending up to 6 months was carried out to compare the effects of nicergoline, 60 mg daily, and placebo in 315 patients suffering from mild to moderate dementia. "
01/01/2001 - "To determine whether there is evidence of efficacy of nicergoline in the treatment of dementia and other age-associated forms of cognitive decline,and to assess the safety and tolerability of the drug. "
01/01/2001 - "Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment."
01/01/1997 - "Relations between symptomatology and brain function in dementias: double-blind, placebo-controlled, clinical and EEG/ERP mapping studies with nicergoline."
01/01/1972 - "[Effect of nicergoline on energy metabolism in the brain in ischemia]."
11/03/1999 - "In the present study, rats treated with nicergoline (32 mg/kg, i.p.), an ergot alkaloid derivative, showed minimal inhibition of the [Glu](e) elevation which characteristically occurs during the 10-min intraischemic period, while Glu re-uptake was dramatically improved in the postischemic period, when severe transient global ischemia was caused by mild hyperthermia. "
11/01/1983 - "Thus nicergoline reduced severity of ischemia and afforded protection against arrhythmias induced by myocardial ischemia and reperfusion. "
08/01/1987 - "The cerebroprotective effect of nicergoline was studied using the following experimental methods: hypobaric and anoxic hypoxia in mice, complete ischemia by decapitation in mice, incomplete ischemia by bilateral carotid ligation in rats, hemic hypoxia in rats and asphyxic anoxia in cats. "
08/01/1987 - "In hypobaric hypoxia and complete ischemia by decapitation the interaction of nicergoline with the effect of prostacyclin (PGI2) was investigated. "
01/01/2008 - "Although clinical experience with nicergoline in vascular disorders is limited to relatively short-term, small-scale studies, it has been successfully used in rehabilitation therapy of patients with chronic ischaemic stroke. "
11/01/2002 - "25 patients with neurological and neuropsychological deficits after a mild ischaemic stroke were treated with nicergoline (Adavin 60 mg/d) versus placebo in a double blind cross-over trial (3 and 3 months). "
11/01/2002 - "[Nicergoline in the treatment of patients after a mild ischemic stroke]."
01/01/1997 - "According to the above results the beneficial influence of nicergoline and pentoxiphylline treatment of ischaemic stroke was not confirmed."
07/01/1988 - "[Use of sermion in cerebral atherosclerosis patients with a history of ischemic stroke]."
|4.||Hypertension (High Blood Pressure)
04/01/1985 - "A previous study in the same conditions with another alpha 1-adrenoreceptor blocking agent, nicergoline, showed an inhibition of hypertension development in G 1 rats together with a preventive effect on untreated G 2 SHR (Moore et al., 1983). "
10/01/1987 - "[Use of nicergoline (IDB-1076) in the treatment of mild to moderate systemic arterial hypertension in adults and in the aged]."
11/01/1985 - "In order to test the therapeutic action of nicergoline during peroperative arterial hypertension, an intravenous perfusion of 5 mcg/kg/mn average dose was given to 15 patients which presented a peroperative increase of Systolic Blood Pressure (SBP) greater than 30% when compared with preanaesthetic corresponding value. "
01/01/1983 - "Effects of parenteral treatment by nicergoline on the development of hypertension of S.H.R."
12/20/1980 - "The remarkable effectiveness and tolerance of nicergoline make it a highly suitable agent for the treatment of hypertension in elderly people."
04/01/1989 - "Nicergoline was effective in 13/15 patients, eight of these patients having a complete remission of pruritus. "
04/01/1989 - "This study demonstrated that some hemodialyzed patients with pruritus of unknown etiology had improvement with nicergoline."
04/01/1989 - "All patients with pruritus entered in a crossover, double-blind trial with nicergoline. "
04/01/1989 - "Double-blind, placebo-controlled study of nicergoline in the treatment of pruritus in patients receiving maintenance hemodialysis."
12/08/1984 - "[Favorable effect of nicergoline on pruritus in chronic hemodialysis patients. "
|4.||Ergoloid Mesylates (Hydergine)
|2.||Renal Dialysis (Hemodialysis)